Clinical trials
Limited Stage Small Cell Lung Cancer clinical trials
Below are recruiting limited stage small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 469 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07548060RecruitingPhase 2
New drug combination for advanced lung cancer after prior treatments
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07565532Recruiting
Small Cell Lung Cancer Treatment Study With Radiation
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07583511RecruitingPhase 2
New drug combination for advanced lung cancer
This study tests whether a combination of three drugs—teniposide, cisplatin, and serplulimab—can effectively treat extensive-stage small cell lung cancer (a fast-growing type of lung cancer that has spread). Serplulimab is an immunotherapy drug designed to help your immune system fight cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07594522RecruitingPhase 1/Phase 2
Ivonescimab with Radiation for Early Lung Cancer
This trial tests a new immunotherapy drug called ivonescimab combined with focused radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer who cannot or prefer not to have surgery. The goal is to see if this combination can effectively treat the cancer while being tolerable.
Basking Ridge, New JerseyAges 18 years+ - NCT07596121RecruitingPhase 2
Serplulimab for Advanced Lung Cancer in Older Adults
This trial tests a new immunotherapy drug called serplulimab in patients aged 65 and older with advanced non-small cell lung cancer (NSCLC). The drug works by helping your immune system fight cancer cells that have a specific marker called PD-L1.
Xi'an, ShannxiAges 65 years+ - NCT07619339RecruitingPhase 1
Tepotinib and Ivonescimab for MET-Driven Lung Cancer
This trial tests a combination of two drugs (tepotinib and ivonescimab) for advanced non-small cell lung cancer patients whose tumors have a specific genetic change called MET exon 14 skipping. The goal is to see if this combination can slow or shrink the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT07637448RecruitingPhase 2
EGFR-targeted therapy plus immunotherapy for advanced lung cancer
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18 years+ - NCT07637474Recruiting
Immune System and Lung Cancer Response to Immunotherapy
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
Rome, RomeAges 18 years+ - NCT07641023RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Lung Cancer
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT07647094RecruitingEarly Phase 1
Chemotherapy plus immunotherapy for advanced squamous lung cancer
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Quzhou, ZhejiangAges 18–75 - NCT07660094RecruitingPhase 3
New treatment for advanced lung cancer that has stopped responding to immunotherapy
This trial tests a new investigational medicine (aglatimagene besadenovec) plus pembrolizumab against standard chemotherapy (docetaxel) for people with stage IV non-squamous lung cancer that has stopped responding to pembrolizumab. The new treatment is given as a tumor injection (like a biopsy) along with a pill (prodrug) and an infusion of pembrolizumab. The goal is to see if it can re-engage the immune system to fight the cancer.
New York, New YorkAges 18 years+ - NCT07285434Enrolling by invitationEarly Phase 1
Personalized vaccine for first-line advanced lung cancer
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Thessaloniki, MacedoniaAges Any age - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06816966Enrolling by invitationPhase 2
Chemo-immunotherapy with split radiation for extensive-stage lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and a special type of radiation given in split sessions for people with extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better.
Fuzhou, FujianAges 18 years+ - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT06759857Enrolling by invitationPhase 3
New drug vs. afatinib for EGFR-mutant lung cancer
This trial compares a new drug (FHND9041) to a standard targeted therapy (afatinib) for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if the new drug works better or has fewer side effects.
BeijingAges 1.5 years+ - NCT06370416Enrolling by invitationPhase 2
Preventing bone marrow suppression from chemo in advanced lung cancer
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Zhengzhou, HenanAges 18 years+ - NCT06250777Enrolling by invitationPhase 2
T-DXd for HER2-mutant lung cancer with brain metastases
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
SeoulAges 20 years+ - NCT06768151RecruitingPhase 1
CEA-targeting car-t therapy for advanced lung cancer
This trial tests a new treatment called CAR-T therapy that targets a protein called CEA found on some lung cancer cells. It is for people with advanced lung cancer that has not responded to or has gotten worse after at least two standard treatments.
Wuhan, HubeiAges 18 years+ - NCT06563999RecruitingPhase 2
Study of new drugs for stage III lung cancer with rare gene changes
This trial tests whether giving treatment before surgery (neoadjuvant therapy) can help people with stage III lung cancer that has certain rare gene changes. The goal is to see if this approach can shrink the tumor enough to allow surgery.
Guangzhou, GuangdongAges 18–75 - NCT07501650RecruitingPhase 1
Pembrolizumab plus ultrasound bubbles for head and neck cancer
This trial combines the immunotherapy drug pembrolizumab (Keytruda) with a special ultrasound technique that uses tiny bubbles to make the treatment work better. It is for people with HPV-negative head and neck cancer that has come back or spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06332274RecruitingPhase 3
Tislelizumab for cancer patients with minimal residual disease
This trial is for people who have completed standard cancer treatments (like surgery, chemo or radiation) and have no visible cancer on scans, but may still have very small amounts of cancer DNA in their blood. The study tests whether the drug tislelizumab can help prevent the cancer from coming back.
Villejuif, Val De MarneAges 18 years+ - NCT06019455Recruiting
How patients participate in lung and esophageal cancer care
This study looks at how much patients with lung or esophageal cancer get involved in decisions about their care when they receive chemotherapy and radiation together. It aims to learn what helps or challenges patients in taking an active role.
GuangzhouAges 18–75
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for limited stage small cell lung cancer?
- Yes. Clin2 currently lists 469 recruiting limited stage small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a limited stage small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a limited stage small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Small Cell Lung Cancer Extensive Stage
- Non-small Cell Lung Cancer Stage III
- Non Small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Stage IIIA Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Squamous Cell Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.